论文部分内容阅读
目的探讨常规抗心力衰竭(心衰)治疗联合磷酸肌酸钠对心瓣膜病所致慢性心衰患者的心功能及其BNP的影响。方法选取2013年8月—2015年8月于本院接受治疗的80例心瓣膜病引起的心衰患者为研究对象,运用随机数字表法将其分为两组,各40例。对照组采用常规抗心衰治疗方法进行治疗。观察组在对照组基础上加用磷酸肌酸钠,1.0 g的磷酸肌酸钠与100 ml浓度为0.9%的氯化钠注射液混合,静脉注射,2次/d,7 d为一个疗程,治疗时间为两个疗程。比较治疗前后两组患者的心功能及BNP水平。计量资料采用t检验,P<0.05为差异有统计学意义。结果治疗后观察组LVEF、LVDd、E/A值、心率分别为(63.51±5.90)%、(50.31±5.89)mm、(1.15±0.12)、(69.32±11.21)次/min,对照组为(60.11±4.39)%、(59.69±6.18)mm、(0.87±0.19)、(80.12±13.02)次/min,观察组患者心功能明显优于对照组,对比差异均有统计学意义(均P<0.05)。治疗后观察组BNP水平为(221±38)pg/ml,对照组为(254±29)pg/ml,对比差异均有统计学意义(均P<0.05)。结论常规抗心衰治疗联合磷酸肌酸钠能有效改善心瓣膜病所致慢性心衰患者的心功能及BNP水平,疗效显著。
Objective To investigate the effects of conventional anti-heart failure (CHF) combined with sodium creatine phosphate on heart function and BNP in patients with chronic heart failure caused by valvular heart disease. Methods Eighty patients with heart failure caused by valvular heart disease in our hospital from August 2013 to August 2015 were enrolled in this study. Patients were divided into two groups (n = 40) by random number table. Control group using conventional anti-heart failure treatment for treatment. On the basis of the control group, the observation group was given sodium creatine phosphate, 1.0 g of sodium creatine phosphate and 100 ml of 0.9% sodium chloride injection. The rats in the observation group were given intravenous injection twice a day for 7 days, Treatment time is two courses. The cardiac function and BNP level in both groups before and after treatment were compared. Measurement data using t test, P <0.05 for the difference was statistically significant. Results After treatment, the values of LVEF, LVDd, E / A and heart rate in the observation group were (63.51 ± 5.90)%, (50.31 ± 5.89) mm, (1.15 ± 0.12) and (69.32 ± 11.21) (60.11 ± 4.39)%, (59.69 ± 6.18) mm, (0.87 ± 0.19) and (80.12 ± 13.02) times / min respectively. The cardiac function in the observation group was significantly better than that in the control group (all P < 0.05). The level of BNP in the observation group after treatment was (221 ± 38) pg / ml and in the control group was (254 ± 29) pg / ml, the difference was statistically significant (all P <0.05). Conclusion Conventional anti-heart failure treatment combined with sodium creatine phosphate can effectively improve heart function and BNP levels in patients with chronic heart failure caused by valvular heart disease.